ProbioticLactobacillusspp. DiminishHelicobacter hepaticus-Induced Inflammatory Bowel Disease in Interleukin-10-Deficient Mice

Open Access
Publisher Website
Google Scholar
Abstract
Clinical and experimental evidence has demonstrated the potential role of probiotics in the prevention or treatment of inflammatory bowel disease. Probiotic clones with direct immunomodulatory activity may have anti-inflammatory effects in the intestine. We investigated the roles of tumor necrosis factor alpha (TNF-α)-inhibitoryLactobacillusclones with a pathogen-induced murine colitis model. Murine-derived probiotic lactobacilli were selected in vitro for their ability to inhibit TNF-α secretion byHelicobacter hepaticus-stimulated macrophages. Interleukin-10 (IL-10)-deficient mice were treated with probioticLactobacillus reuteriin combination withLactobacillus paracaseiand then challenged withH. hepaticus. Ten weeks postinoculation, the severity of typhlocolitis was assessed by histologic examination of the cecocolic region. Intestinal proinflammatory cytokine responses were evaluated by real-time quantitative reverse transcriptase PCR and immunoassays, and the quantities of intestinalH. hepaticuswere evaluated by real-time PCR. Intestinal colonization by TNF-α-inhibitory lactobacilli reduced intestinal inflammation inH. hepaticus-challenged IL-10-deficient mice despite similar quantities ofH. hepaticusin cocolonized animals. Proinflammatory colonic cytokine (TNF-α and IL-12) levels were lowered inLactobacillus-treated animals. In thisH. hepaticus-challenged IL-10-deficient murine colitis model, lactobacilli demonstrated probiotic effects by direct modulation of mucosal inflammatory responses.

This publication has 43 references indexed in Scilit: